Background: Because of the less graft-facilitating effect by bone marrow (BM), we need to assess a dosage of conditioning more accurately particularly in combination with reduced-intensity conditioning. Thus we examined that modified continual reassessment method (mCRM) is applicable for deciding appropriate conditioning of allogeneic BM transplantation.
introduction
The development of a reduced-intensity conditioning (RIC) regimen has enabled older patients or those with comorbidities who are not expected to tolerate the toxicity of myeloablative conditioning to be treated with allogeneic hematopoietic stem-cell transplantation (HSCT) [1] [2] [3] [4] . The aim of developing these regimens is to reduce early treatment-related mortality (TRM) while these regimens are still achieving hematopoietic and donor-immune cell engraftment to exert a graft-versusleukemia (GVL) effect [5] . To assure donor engraftment, most studies use granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells (G-PBSC) with substantial numbers of CD34+ cells and T cells [6] , while the immunosuppression required for engraftment is usually accomplished with the fludarabine plus a cytotoxic agent or low-dose total-body irradiation [1] [2] [3] . Earlier experiences have shown that the risk of rejection after bone marrow transplantation (BMT) is substantially higher than that of peripheral-blood stem cell transplantation (PBSCT) in RIC transplantation [7] . However, PBSCT from unrelated donors is not currently available in Japan, and bone marrow (BM) may be a more suitable graft source to avoid severe graft-versus-host disease (GVHD), which often leads to TRM [8] . Therefore, a better dosage of conditioning is needed to ensure engraftment in RIC with BM.
Although no one has attempted to systematically conduct a phase I study in conditioning regimen, we adopted a systematic phase I approach by using a modified continual reassessment method (mCRM) to more accurately assess the original article *Correspondence to: Dr S. Terakura, Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi 466-8550, Japan. Tel: +81-52-744-2145; Fax: +81-52-744-2161; E-mail: tseit@med.nagoya-u.ac.jp dosage of a conditioning regimen and to minimize the potential risk of graft failure [9] [10] [11] [12] . The mCRM was originally a toxicity-based method that has been shown to be feasible in dose-escalating trials and that has been hypothesized to allow a reduction in patients needed to reach the recommended dose compared with the classical phase I trial design (modified Fibonacci method). We selected the fludarabine plus melphalan regimen that has sufficient potential to induce BM engraftment if melphalan is used at 180 mg/m 2 [13] , and further optimization of the melphalan dosage is planned. The rationale for modulating the dose of melphalan resulted from accumulated observations that melphalan alone is associated with toxic effects, while fludarabine is not [14] . Because the optimal dose of melphalan to minimize regimen-related toxic effects (RRTs) and to enable sustained engraftment remains unknown to date, we investigated the recommended dose of melphalan as a phase I study. We showed the recommended dose of melphalan for a future phase II study.
patients and methods

patient and donor eligibility
The potential confounding factors that can influence engraftment efficiency were controlled by eligibility criteria as follows. Eligibility criteria included patients with hematological malignancies who have had more than three courses of chemotherapy, aged between 55 and 65 years or between 40 and 54 years with substantial comorbidity (the hematopoietic cell transplantation comorbidity index (HCT-CI) of ‡1) [15] , and no prior stem-cell transplantation. Patients were excluded if they had any of the following: (i) clinically significant infectious disease; (ii) plan to deplete T cells from graft and (iii) severe abnormalities of cardiac, pulmonary, and hepatic functions corresponding to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade 3 [16] .
All donors were unrelated volunteers recruited through the Japan Marrow Donor Program. Donors were required to be human leukocyte antigen (HLA)-A, -B, and -DRB1 identical or -A, -B identical and -DRB1-1 locus mismatch with their patients based on oligonucleotide typing or DNA sequencing [17, 18] . The protocol was approved by the institutional review boards of all participating institutions. All patients and donors provided written informed consent.
study design and dose determination
To adjust the melphalan dose, we adopted an mCRM that has been hypothesized to allow faster and more accurate dose reduction/escalation in patients needed to reach the recommended dose compared with a classical algorithmic dose modification design [9, 10, 12] 
study endpoints and definitions
Primary endpoint was to achieve the donor-type T-cell chimerism at day 28, with successful engraftment defined as ‡90% donor cells. Secondary endpoints were hematopoietic recovery, RRT within 30 days after transplant, incidence and severity of acute and chronic GVHD, overall survival (OS) and event-free survival (EFS). The day of neutrophil engraftment was defined as the first of the three consecutive days on which the neutrophil count exceeded 500/ll, while platelet engraftment was defined as the first of the three consecutive days when the absolute platelet count exceeded 20 000/ll without platelet infusion. Patients who did not reach neutrophil counts of >500/ll by day 28 after transplantation were considered as having a primary graft-failure. Patients with initial engraftment in whom absolute neutrophil counts declined to <500/ll subsequently were considered to have secondary graft-failure.
conditioning regimens
The conditioning regimen consisted of five doses of fludarabine 25 mg/m 2 administered i.v. on days 26 to 22 combined with two doses of melphalan i.v. on days 23 and 22. Criteria for determination of the melphalan dose are described elsewhere in detail. BM grafts were infused on day 0.
GVHD prophylaxis and grading
GVHD prophylaxis consisted of tacrolimus plus short-course methotrexate [19] . Acute and chronic GVHD were graded by established criteria [20, 21] .
chimerism analysis
Serial samples of peripheral-blood mononuclear cells were analyzed for degrees of donor-recipient chimerism using a PCR of informative microsatellite regions after transplantation, as described previously [22] . Samples were routinely analyzed on days 14, 28, 56 and 84, or in cases of disease recurrence or suspicion of graft failure.
statistical analysis
All eligible patients were subjects for analyses of efficacy secondary endpoints. One patient with a protocol violation was excluded for efficacy analyses and GVHD analyses. All patients given conditioning chemotherapy were the subjects for analyses of safety secondary endpoints. Cumulative incidence curves were used in a competing-risks setting to calculate the probability of acute and chronic GVHD, relapse and TRM. For GVHD, death without GVHD; for relapse, death without relapse and for TRM, relapse was the competing event. Curves for EFS and OS were plotted according to the method of a Kaplan-Meier estimate and were compared by the log-rank test [23] . A significance level of Annals of Oncology diseases were advanced in 11 patients (65%), while HCT-CI at the time of transplantation was 0 in 7 patients, 1 in 5 patients, 2 in 3 patients and 3 in 2 patients. A total of 17 patients were enrolled at doses between 130 and 160 mg/m 2 , including one protocol violation for whom cyclosporine A was used as GVHD prophylaxis instead of tacrolimus (patient 2) and one early death (brain hemorrhage, patient 12; Table 2 ). Both were unavailable in advance for an assessment of the primary endpoint according to the study definition.
The median donor age was 33 years (range 26-48). Donors were HLA-identical (6/6 match) in 13 patients and non-identical (5/6 match) in 4 patients. All non-identical donors were HLA-DRB1 allele mismatch. Because HLA-C typing was not essential for this study enrollment, some data were unavailable. As far as we could tell, all but one donor-patient pair (patient 8) were matched in the HLA-C allele (Table 2 ). Patient 8 was also mismatched in the HLA-DRB1 allele.
The median infused cell dose was 2.36 · 10 8 /kg (range 0.54 to 3.98 · 10 8 /kg), and the median infused CD34+ cell dose was 2.31 · 10 6 /kg (range 1.52 to 5.45 · 10 6 /kg).
analysis of primary endpoint: conditioning regimen, engraftment and chimerism
The melphalan doses given to patients are summarized in Table 2 , and the chimerism analysis data of each leukocyte fraction are depicted ( Figure 1A-D) . Five consecutive full-donor chimerisms (all were 100% at day 28) were observed in the first level (160 mg/m 2 ). The summed response score of the first level was 5.0. The melphalan dose for the next level was calculated as 102.5 mg/m 2 using the mCRM program. The upper limitation rule of dose modification was then applied, and the second dose was determined as 130 mg/m 2 . In the second level, we observed four patients with 100% chimera and one with 0% chimera at day 28, which eventually resulted in a secondary graft-failure (patient 8). The next melphalan dose following the second level (summed response score = 4.0) was calculated to be 133.1 mg/m 2 , which was rounded off to 135 mg/m 2 (third level). In the third level, five consecutive full-donor chimerisms (four 100% and one 90.4%) were observed (summed response score = 5.0). Since the calculated dose for the next level was 130.0 mg/m 2 , which was within 5 mg/m 2 of the melphalan dose in the third level in which all patients were successfully engrafted, the study was complete as projected. Overall neutrophil engraftment was achieved in all patients at a median of 14 days (range 12-18) after transplant, which was comparable with the previous data of RIC transplantation, with sustained engraftment achieved in 14 of 15 (93.3%) patients.
Full-donor chimerism had been lost in 2 of 15 assessable patients until day 100. Patient 8 was an HLA-C and -DRB1 allele-mismatched case and consequently developed secondary graft-failure. Patient 8 showed 100% donor chimerism at day 14 but was lost completely at day 28 and developed graft failure. The peripheral leukocyte count was initially recovered on day 15 but gradually fell to 400/ll (100% lymphocyte) by day 25, and BM was severely hypoplastic. Patient 17 achieved 90.4% donortype T-cell chimerism at day 28 ( Figure 1A) , then lowered to 75.2% at day 56 and 80.4% at day 84. That patient was diagnosed with a cytogenetic relapse at day 54 and a hematological relapse at day 89. Patient 13 was diagnosed with a hematological relapse at day 84. Thus sustained engraftment at day 100 or until relapse was obtained in 14 of 15 (93%) assessable patients. Continued engraftment at 1 year after transplant was observed among 10 of 10 assessable patients (Table 2 ). There was no late rejection among enrolled patients. secondary endpoints toxicity. Toxic effects of 17 assessable patients within day 28 are graded according to the NCI-CTCAE version 3.0 and summarized in Table 3 . Conditioning was generally well tolerated and in concordance with the expected adverse-effect profile of fludarabine plus melphalan conditioning. Grade 3 mucositis, nausea/vomiting and diarrhea were the main toxic effects, affecting 35%, 59% and 24% of the assessable patients, respectively. There was no statistically significant difference in the toxicity grade among dose levels (mucositis, P = 0.23; nausea/vomiting, P = 0.51; diarrhea, P = 0.24; Kruskal-Wallis test). All grade 4 toxic effects were from patient 2 and patient 12. The former developed severe veno-occlusive disease, while patient 12 developed a brain hemorrhage. During their course, they also exhibited severe pulmonary infection (patient 2) and cardiac arrest (patient 12).
GVHD. Of 16 assessable patients, acute GVHD grade I was observed in only one, and the onset was day 22. The cumulative incidence of acute GVHD at day 100 was 6% [95% confidence interval (CI) 0% to 25%]. Five of 13 assessable patients Acute leukemia in first complete remission, chronic myelogenous leukemia in first chronic phase, and malignant lymphoma in complete remission were defined as standard risk. All other conditions were defined as advanced risk. developed chronic GVHD, with de novo onset in all 5 cases (limited type in 2 patients and extensive type in 3), for a 1-year cumulative incidence of chronic extensive GVHD of 31% (95% CI 11% to 54%).
survival. The median follow-up of survivors was 2.6 years (range 1.8-3.8 years), while the OS of eligible patients without a protocol violation (n = 16) was 52% (95% CI 23% to 74%) at 3 years. EFS was 44% (95% CI 20% to 67%) at 3 years ( Figure 2A ). Differences in OS and EFS among the dose levels were not significant (P = 0.70 and P = 0.74, respectively).
A relapse was observed in five patients between days 54 and 265, and the cumulative incidence of relapse at 1 year was 31% (95% CI 11% to 54%; Figure 2B ). Among the dose levels, no differences in the incidence of relapse were observed (two patients in the first level, one in the second and two in the third; P = 0.83, Gray's test). The cumulative incidence of TRM at 1 year was 24% (95% CI 7% to 45%). (Table 4 ). The mortality was observed in five of five in the first level, two of five in the second and two of five in the third. One patient in the first level died of chronic GVHD and another in the first level died of invasive toxoplasmosis; one patient in the second level died of secondary graft-failure. One in the first level died of the sustained disease throughout the transplantation (patient 6). A relapse was observed in five patients and was the leading cause of death in the current study.
discussion
The dosage of conditioning regimen for HSCT has not so far been determined systematically. Since we could not predict the optimal dose modification breadth and there were some promising data to show the usefulness of mCRM in dosefinding study of cancer patients [24, 25] , we adopted the mCRM instead of the classical phase I approach with fixed dose levels. The stable engraftment at day 28 was defined as a primary endpoint instead of dose-limiting toxicity, which led us to the recommended dose adequately. We evaluated five patients at each dose level by using a feature of mCRM in which investigators could set the number of patients per dose level flexibly. One patient developed secondary graft-failure [6.3% (95% CI 0% to 30%)], a result comparable with previous reports from an unrelated BMT [26, 27] . Collectively, these results suggest that the mCRM for a conditioning regimen is a faster and safer method to determine the recommended phase II dosage.
To secure an engraftment and detect a potential effect of a modifying conditioning drug dosage on to the engraftment, we employed chimerism at a very early time point (day 28) as a primary endpoint and restricted the maximum dose modification breadth to 30 mg/m 2 to reduce the risk of graft failure. Unfortunately, we observed one secondary graft-failure even though we put a special stress on safety. However, this was the only patient mismatched in both the HLA-C and HLA-DRB1 alleles. There was also a major mismatch in ABO blood type so that the patient received the lowest number of total nuclear cells after red blood cell depletion, suggesting that both factors happened to coincide to develop this patient's secondary graft-failure [18, 28] . Although RRTs were measured by day 28 in the current study, no significant differences were observed among dose levels. In fact, we observed a very small number of toxic effects, particularly in the early time point (data not shown). Because the primary endpoint was settled as early stable chimerism, this study could be completed earlier. Mucositis  13  5  2  6  0  3  0  2  3  2  3  Nausea/vomit  14  3  1  10  0  2  2  1  5  1  3  Diarrhea  13  4  5  4  0  4  0  2  3  3  1  Skin rash  4  2 Probability of EFS was 50% (95% CI 25% to 71%) at 1 year and 44% (95% CI 20% to 67%) at 3 years after transplant. (B) Cumulative incidence of relapse was 31% (95% CI 11% to 54%) at 1 year after transplant. EFS, event-free survival; CI, confidence interval.
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Taken together, we believe that mCRM with early chimerism/ engraftment as a primary endpoint is a good tool for dosefinding of HSCT conditioning. Only one grade I acute GVHD [6% (95% CI 0% to 25%)] and no grade II-IV acute GVHD was observed in the current study, which seems considerably low, compared with other RIC-PBSCT series from HLA-matched unrelated donors [29] . This may be due to our ethnicity and/or graft source [30] or due to the strength of conditioning. As we typically observe 35% of grade II-IV and 13% of grade III-IV acute GVHD on the basis of an HLA-match/DRB1-1 locus mismatch unrelated donor, it would be due not only to ethnicity but also to BM graft [18] . BM includes far fewer CD8+ T cells than G-PBSC, which might be attributable to the low incidence of GVHD in our patients. Since CD8+ cells in grafts have been shown to play an important role in facilitating engraftment [31] [32] [33] , we should be much more careful about the conditioning dosage in BMT. Another possibility is that the strength of conditioning might be exactly adequate, leading to a modest engraftment in the current transplant settings [34] . A deeper understanding of dose-engraftment relationships in future may contribute to more stable engraftment as well as to a lower incidence of acute GVHD by RIC-BMT. On the other hand, a significant proportion of patients developed chronic GVHD [31% (95% CI 11% to 54%)], which was almost comparable with that in previous reports of conventional BMT [18, 26] . Because the incidence of chronic GVHD is a candidate surrogate for the GVL effect [5] , this observation may prove beneficial for patients.
Our results verified that fludarabine plus a melphalan regimen was generally well tolerated and highly immunosuppressive. Although our follow-up is still too short to draw any conclusion about survival, given that five relapses (31%) were observed in the current study, we might consider adding some tumor-specific cytotoxic agents such as radioimmunoantibodies to reduce the likelihood of relapse [35, 36] . The OS and EFS were comparable with the previous age-matched data [37] . Further studies are warranted to confirm a long-term efficacy, particularly for lower-risk patients.
In conclusion, a phase I dose-finding study using mCRM was completed. The strategy using engraftment instead of toxicity as a primary endpoint might result in a better chance to determine the optimal dosage. Our findings have demonstrated that a melphalan dose of 135 mg/m 2 in combination with fludarabine is recommended for a further phase II evaluation.
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